This is all very selective data interpretation. Sofosbuvir does...

This is all very selective data interpretation. Sofosbuvir does not cure all G3 on its own or with ribavirin, but in combination with a NS5a inhibitor e.g. ledipasvir, it probably will given an adequate course. Gilead are also recruiting for a phase 2 trial of their next NS5a inhibitor in G3 patients in case they don't get to 100%. BIT225 getting a 100% RVR in a few G3 patients with riba/IFN isn't awfully startling as riba/IFN probably have an up to 80% chance on their own in the patients selected. Not working in IL28B T allele patients would be a bit concerning for potential partners as well - even boceprevir works in about half of these patients. The interactions with HIV drugs are of boceprevir and telaprevir, two drugs that were effectively obsolete by the time of their release in Australasia. Ledipasvir has minimal hepatic metabolism so I'd be surprised if there was significant interaction with ARTs. The HCV treatment world is awash with phase 2 and 3 clinical trials of a variety of 3rd generation protease inhibitors and polymerase inhibitors - if BIT was not already involved in these there's not much chance they're likely to be picked up now unless there's some pretty unexpected results.